These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27010756)

  • 1. Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs.
    O'Connor LJ; Cazares-Körner C; Saha J; Evans CN; Stratford MR; Hammond EM; Conway SJ
    Nat Protoc; 2016 Apr; 11(4):781-94. PubMed ID: 27010756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A.
    Cazares-Körner C; Pires IM; Swallow ID; Grayer SC; O'Connor LJ; Olcina MM; Christlieb M; Conway SJ; Hammond EM
    ACS Chem Biol; 2013 Jul; 8(7):1451-9. PubMed ID: 23597309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38.
    Jin C; Zhang Q; Lu W
    Eur J Med Chem; 2017 May; 132():135-141. PubMed ID: 28350997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase.
    Zhu R; Seow HA; Baumann RP; Ishiguro K; Penketh PG; Shyam K; Sartorelli AC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6242-7. PubMed ID: 22932317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
    Sansom GN; Kirk NS; Guise CP; Anderson RF; Smaill JB; Patterson AV; Kelso MJ
    Bioorg Med Chem Lett; 2019 May; 29(10):1215-1219. PubMed ID: 30885680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins.
    Jenkins TC; Naylor MA; O'Neill P; Threadgill MD; Cole S; Stratford IJ; Adams GE; Fielden EM; Suto MJ; Stier MA
    J Med Chem; 1990 Sep; 33(9):2603-10. PubMed ID: 2391699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue.
    Damen EW; Nevalainen TJ; van den Bergh TJ; de Groot FM; Scheeren HW
    Bioorg Med Chem; 2002 Jan; 10(1):71-7. PubMed ID: 11738608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
    Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
    Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs.
    Dragovich PS; Broccatelli F; Chen J; Fan P; Le H; Mao W; Pillow TH; Polson AG; Wai J; Xu Z; Yao H; Zhang D
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5300-5304. PubMed ID: 29079474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor.
    Suzuki T; Hisakawa S; Itoh Y; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1558-61. PubMed ID: 17257837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
    Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
    Tokay E; Güngör T; Hacıoğlu N; Önder FC; Gülhan ÜG; Tok TT; Çelik A; Ay M; Köçkar F
    Eur J Med Chem; 2020 Feb; 187():111937. PubMed ID: 31841727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
    Li J; Zheng LM; King I; Doyle TW; Chen SH
    Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
    Tercel M; Lee AE; Hogg A; Anderson RF; Lee HH; Siim BG; Denny WA; Wilson WR
    J Med Chem; 2001 Oct; 44(21):3511-22. PubMed ID: 11585455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
    Lee AE; Wilson WR
    Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reductive Activity and Mechanism of Hypoxia- Targeted AGT Inhibitors: An Experimental and Theoretical Investigation.
    Xiao W; Sun G; Fan T; Liu J; Zhang N; Zhao L; Zhong R
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31847200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.
    Reigan P; Edwards PN; Gbaj A; Cole C; Barry ST; Page KM; Ashton SE; Luke RW; Douglas KT; Stratford IJ; Jaffar M; Bryce RA; Freeman S
    J Med Chem; 2005 Jan; 48(2):392-402. PubMed ID: 15658853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
    El-Dakdouki MH; Adamski N; Foster L; Hacker MP; Erhardt PW
    J Med Chem; 2011 Dec; 54(23):8224-7. PubMed ID: 22011244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
    Ghedira D; Voissière A; Peyrode C; Kraiem J; Gerard Y; Maubert E; Vivier M; Miot-Noirault E; Chezal JM; Farhat F; Weber V
    Eur J Med Chem; 2018 Oct; 158():51-67. PubMed ID: 30199705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.